GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » EV-to-EBIT

LLY (Eli Lilly and Co) EV-to-EBIT : 76.68 (As of Oct. 31, 2024)


View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Eli Lilly and Co's Enterprise Value is $831,510 Mil. Eli Lilly and Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $10,845 Mil. Therefore, Eli Lilly and Co's EV-to-EBIT for today is 76.68.

The historical rank and industry rank for Eli Lilly and Co's EV-to-EBIT or its related term are showing as below:

LLY' s EV-to-EBIT Range Over the Past 10 Years
Min: 19.49   Med: 31.58   Max: 103.65
Current: 86.48

During the past 13 years, the highest EV-to-EBIT of Eli Lilly and Co was 103.65. The lowest was 19.49. And the median was 31.58.

LLY's EV-to-EBIT is ranked worse than
91.59% of 666 companies
in the Drug Manufacturers industry
Industry Median: 17.615 vs LLY: 86.48

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Eli Lilly and Co's Enterprise Value for the quarter that ended in Sep. 2024 was $0 Mil. Eli Lilly and Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $10,845 Mil. Eli Lilly and Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was %.


Eli Lilly and Co EV-to-EBIT Historical Data

The historical data trend for Eli Lilly and Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co EV-to-EBIT Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.50 23.01 42.58 50.68 77.64

Eli Lilly and Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.27 77.64 89.15 87.45 -

Competitive Comparison of Eli Lilly and Co's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's EV-to-EBIT falls into.



Eli Lilly and Co EV-to-EBIT Calculation

Eli Lilly and Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=831510.309/10844.6
=76.68

Eli Lilly and Co's current Enterprise Value is $831,510 Mil.
Eli Lilly and Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,845 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eli Lilly and Co  (NYSE:LLY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Eli Lilly and Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 ) =EBIT / Enterprise Value (Q: Sep. 2024 )
=10844.6/0
= %

Eli Lilly and Co's Enterprise Value for the quarter that ended in Sep. 2024 was $0 Mil.
Eli Lilly and Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,845 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eli Lilly and Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Executives
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Johna Norton officer: Senior VP, Global Quality LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi officer: SVP & CFO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285